EMA: 5 product-specific guidances adopted [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-08-03 18:52 (1884 d 23:35 ago) – Posting: # 19133
Views: 4,357

Dear all,

today the EMA published another set of product-specific guidances (adopted by the CHMP 26 July, effective with 2 February 2019):
  1. Agomelatine tablet 25 mg
  2. Posaconazole gastro-resistant tablet 100 mg
  3. Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg
  4. Cholic acid capsules 50 mg and 250 mg
  5. Vismodegib hard capsule 150 mg

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,628 registered users;
11 visitors (0 registered, 11 guests [including 1 identified bots]).
Forum time: 18:28 CEST (Europe/Vienna)

Restlessness is discontent –
and discontent is the first necessity of progress.
Show me a thoroughly satisfied man 
and I will show you a failure.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz